Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Recursion (Nasdaq: RXRX) will report first quarter 2026 business updates and financial results on Wednesday, May 6, 2026, before market open.
Rhea-AI Summary
Recursion (Nasdaq: RXRX) will report first quarter 2026 business updates and financial results on Wednesday, May 6, 2026, before market open. The company will host a public Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST and stream live on Recursion's X, LinkedIn, and YouTube accounts. Investors may submit questions via the company form link provided.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RXRX
In the Apr 29 session, RXRX declined 3.23%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- May 6, 2026
- First quarter 2026 results release before market open
- Call time ET
- 8:00 am ET
- Scheduled earnings call on May 6, 2026
- Call time MT
- 6:00 am MT
- Scheduled earnings call on May 6, 2026
- Call time BST
- 1:00 pm BST
- Scheduled earnings call on May 6, 2026
Previous Earnings date Reports
-
Set expectations for Q4 and full‑year 2025 results and call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets.
Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the timing of the filing of quarterly earnings; the occurrence and timing of an investor call; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact media@recursion.com Investor Contact investor@recursion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.